Dyne Therapeutics (Nasdaq: DYN) will release topline data from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial for zeleciment rostudirsen (DYNE‑251) on December 8, 2025.
The company will host an investor conference call and webcast at 8:00 a.m. ET. A press release will precede the event, and the webcast, together with a slide deck, will be posted on Dyne’s Events & Presentations page. A replay will be available for 90 days.
Key Figures
Market Reality Check
$20.28 Last Close
Volume Volume 2,571,519 is 1.09× the 20‑day average of 2,357,527, indicating modestly elevated trading ahead of the data release.
Technical Shares are trading above the 200‑day moving average of $13.11, reflecting a pre‑existing uptrend.
Peers on Argus 1 Up
DYN fell 2.27 % while peers showed mixed moves: SRPT –2.73 %, IMCR –3.22 %, PROK –8.95 %, MESO +1.77 %, HRMY +4.08 %. The lack of a uniform sector reaction suggests the upcoming REC data will be the primary driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Quarterly earnings and pipeline update | Positive | ‑2.9 % | Q3 2025 results, cash runway, timelines for DYNE‑251 and DYNE‑101. |
| Nov 03 | Investor conference announcements | Neutral | +6.8 % | Multiple healthcare conference presentations scheduled. |
| Oct 06 | One‑year ACHIEVE Phase 1/2 data for DYNE‑101 | Positive | ‑3.1 % | Functional gains reported in early‑stage study. |
| Oct 02 | Board appointment of Brian Posner | Positive | +4.1 % | Addition of seasoned executive to board. |
| Sep 29 | Japanese orphan‑drug designation for DYNE‑251 | Positive | ‑5.9 % | Regulatory milestone paired with DELIVER data recap. |
Clinically and regulatory positive news often precedes a short‑term price dip, whereas management‑focused updates tend to generate modest upside.
Dyne reported Q3 2025 cash of $791.9 million, projecting a runway into Q3 2027. Despite this liquidity cushion, the stock slipped 2.88 % after the earnings release. Subsequent milestones—ACHIEVE one‑year data, Japanese orphan‑drug designation, and a board appointment—produced mixed price reactions, underscoring the market’s sensitivity to both scientific outcomes and governance signals. The upcoming REC topline call on December 8 will likely reignite that volatility.
Market Pulse Summary
Dyne’s December 8 webcast will deliver the first top‑line readout from the DELIVER Registrational Expansion Cohort for DYNE‑251. Historical data suggests that such clinical milestones can swing the stock sharply in either direction, making the event a focal point for investors. Analysts will be watching how the REC outcomes compare with earlier DELIVER data, the trajectory of the company’s neuromuscular pipeline, and whether the results justify the current valuation upside above the 200‑day moving average.
Key Terms
Webcast
Technical
A live or recorded online broadcast that allows investors and analysts to view corporate presentations in real time or on demand.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Dec. 7, 2025 – Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical‑stage biotech focused on functional improvement for genetically driven neuromuscular diseases, announced the schedule for releasing topline data from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial of zeleciment rostudirsen (DYNE‑251). The company will disclose the results on December 8, 2025, followed by a webcast at 8:00 a.m. ET. A press release will be issued prior to the call.
Investor Conference Call and Webcast
The webcast will be posted on Dyne’s Events & Presentations portal, and a replay will be available for 90 days. Slide decks accompanying the presentation will also be accessible through the same portal.
About Dyne Therapeutics
Dyne is developing therapeutics that target both muscle tissue and the central nervous system to address the root cause of neuromuscular disorders. Its pipeline includes clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as pre‑clinical candidates for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. The company’s mission is to deliver measurable functional improvement for patients, families, and communities.
FAQ
When will Dyne Therapeutics (DYN) announce topline REC results from the DELIVER trial?
Dyne will announce the results on December 8, 2025.
What time is the Dyne Therapeutics (DYN) investor webcast for DELIVER REC results?
The webcast and conference call are scheduled for 8:00 a.m. ET on December 8, 2025.
Where can investors watch the Dyne (DYN) DELIVER REC results webcast and access slides?
Both the webcast and the slide deck will be available on Dyne’s Events & Presentations page.
Will Dyne (DYN) provide a press release before the DELIVER webcast?
Yes. A press release will be issued prior to the start of the webcast.
How long will the replay of Dyne’s (DYN) DELIVER presentation be available?
The replay will be accessible for 90 days after the live event.
What drug and trial does Dyne (DYN) plan to report REC topline results for on December 8, 2025?
Dyne will report REC topline results for zeleciment rostudirsen (DYNE‑251) from the Phase 1/2 DELIVER trial.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14171.html
